Comparing real-world continuous clinical remission rates of anti-tumor necrosis factor, vedolizumab, ustekinumab, tofacitinib, and upadacitinib in ulcerative colitis
Inflammatory Bowel Diseases · 29.10.2026
DOI: 10.1093/ibd/izag229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 29.10.2026. Verfasst von Andrea Cassinotti und 30 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Digestive Endoscopy Unit, ASST Sette Laghi, Varese, Italy. Die Arbeit nennt 58 Literaturangaben.
Abstract (Originalsprache)
Background
Multiple advanced therapies are available for moderate-to-severe ulcerative colitis (UC), but comparative efficacy data are limited. We compared the 1-year efficacy and safety of 7 therapies: the anti-tumor necrosis factor agents infliximab, adalimumab, and golimumab (GLM); the anti-integrin vedolizumab (VDZ); the anti-interleukin-12/23 ustekinumab (UST); and the JAK inhibitors tofacitinib (TOF) and upadacitinib (UPA).
Methods
In a retrospective, multicenter, propensity score–matched study, all UC patients treated with the 7 advanced therapies between 2014 and 2024 were included. The primary endpoint was the 1-year rate of continuous clinical remission (CCR) for each drug (defined as the induction and maintenance of steroid-free clinical remission, without the need for drug optimization or additional therapy due to relapse, with no adverse events requiring drug discontinuation).
Results
A total of 1406 patients were included (VDZ = 376, infliximab = 341, adalimumab = 207, UST = 150, GLM = 114, TOF = 103, UPA = 115). Excluding UPA from the overall population comparison as it was used only in bio-exposed patients, UST achieved the highest CCR, with GLM the lowest. UST appeared the most effective therapy in bio-naive patients, whereas other biologics achieved similar CCR rates. As second-line therapy, UPA achieved the highest CCR, followed by UST. As third-line therapy, UPA outperformed UST, VDZ, and TOF. UST was associated with the lowest rates of adverse events. Although UPA was associated with the highest rates of adverse events, drug withdrawal was low.
Conclusions
In this large multicenter observational cohort, UST was more effective than anti-tumor necrosis factor agents and VDZ as both first- and second-line therapy. In bio-exposed patients, UPA was the most effective advanced therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterology and Digestive Endoscopy Unit, ASST Sette Laghi, Varese, Italy.
- IBD Unit, Gastroenterology Unit, Rho Hospital, ASST Rhodense, Rho, Italy.
- Gastroenterology Unit, Department of Biochemical and Clinical Sciences "L. Sacco," ASST Fatebenefratelli Sacco, University of Milan, Milan, Italy.
- Gastroenterology and Endoscopy Unit, Ospedale Maggiore Policlinico, Fondazione IRCCS Cà Granda, Milan, Italy.
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
- Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy.
ORCID-Profile: Andrea Cassinotti, Simone Saibeni, Giovanni Maconi, Pietro Invernizzi, Antonio Di Sabatino, Maurizio Vecchi
Zitieren
APA
Cassinotti, A., Saibeni, S., Cannatelli, R., Michelon, M., Maconi, G., Caprioli, F., Lepore, F., Lo Bello, A., Annunziata, M. L., Zammarchi, I., Dota, M., Anchieri, E., Casini, V., Delogu, C., Fichera, M., Mezzina, N., Lenti, M. V., Ricci, C., Parravicini, M., …, & A.U.R.O.R.A. 2 Study Group (2026). Comparing real-world continuous clinical remission rates of anti-tumor necrosis factor, vedolizumab, ustekinumab, tofacitinib, and upadacitinib in ulcerative colitis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag229
Vancouver
Cassinotti A, Saibeni S, Cannatelli R, Michelon M, Maconi G, Caprioli F, et al. Comparing real-world continuous clinical remission rates of anti-tumor necrosis factor, vedolizumab, ustekinumab, tofacitinib, and upadacitinib in ulcerative colitis. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag229
BibTeX
@article{Cassinotti2026,
author = {Cassinotti, Andrea and Saibeni, Simone and Cannatelli, Rosanna and Michelon, Marco and Maconi, Giovanni and Caprioli, Flavio and Lepore, Federica and Lo Bello, Antonio and Annunziata, Maria Laura and Zammarchi, Irene and Dota, Michele and Anchieri, Eleonora and Casini, Valentina and Delogu, Claudia and Fichera, Maria and Mezzina, Nicolo' and Lenti, Marco Vincenzo and Ricci, Chiara and Parravicini, Marco and Chapman, Thomas P and Ferraro, Raffaella and Pagano, Nico and Invernizzi, Pietro and Manes, Gianpiero and Annese, Vito and Di Sabatino, Antonio and Segato, Sergio and Vecchi, Maurizio and Ardizzone, Sandro and De Silvestri, Annalisa and A.U.R.O.R.A. 2 Study Group, A.U.R.O.R.A. 2 Study Group},
title = {Comparing real-world continuous clinical remission rates of anti-tumor necrosis factor, vedolizumab, ustekinumab, tofacitinib, and upadacitinib in ulcerative colitis},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izag229}
}
EUVIMED